Keros Therapeutics (NASDAQ:KROS) Trading Up 7.5%

Keros Therapeutics, Inc. (NASDAQ:KROS) shot up 7.5% during mid-day trading on Friday . The company traded as high as $61.92 and last traded at $61.41. 93,008 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 404,823 shares. The stock had previously closed at $57.10.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on KROS. Piper Sandler reaffirmed an “overweight” rating and set a $105.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 27th. William Blair restated an “outperform” rating on shares of Keros Therapeutics in a research report on Wednesday, February 21st. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Friday, March 1st. Truist Financial restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research report on Wednesday, March 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $86.00 price target on shares of Keros Therapeutics in a report on Thursday, February 29th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Buy” and an average target price of $86.00.

Keros Therapeutics Stock Performance

The stock has a 50-day simple moving average of $63.36 and a 200 day simple moving average of $48.64. The stock has a market capitalization of $2.18 billion, a P/E ratio of -11.65 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Friday, March 1st. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $0.14 million for the quarter. During the same period in the previous year, the company earned ($1.09) earnings per share. Equities analysts predict that Keros Therapeutics, Inc. will post -5.11 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Keros Therapeutics by 18.8% in the third quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company’s stock worth $44,837,000 after acquiring an additional 222,652 shares in the last quarter. Braidwell LP increased its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Braidwell LP now owns 1,357,309 shares of the company’s stock worth $43,271,000 after purchasing an additional 213,444 shares during the last quarter. Franklin Resources Inc. increased its holdings in Keros Therapeutics by 47.9% during the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after buying an additional 226,674 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Keros Therapeutics during the fourth quarter worth $27,367,000. Finally, CHI Advisors LLC increased its stake in shares of Keros Therapeutics by 1.4% during the 3rd quarter. CHI Advisors LLC now owns 407,633 shares of the company’s stock worth $12,995,000 after purchasing an additional 5,515 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.